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Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having
mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study
aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting.
Materials and methods: A retrospective, multicenter study conducted in four university hospitals in Turkey between January 2017
and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total
2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity
(FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone
treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage,
where appropriate.
Results: The study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients
discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a
decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated
with the treatment was observed in 28 (37.3%) patients.
Conclusion: Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patients.
Key words: Cough, idiopathic pulmonary fibrosis, treatment

1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a fatal condition
characterized by chronic progressive lung fibrosis [1–3].
Patients with IPF have a 5-year survival rate of 20%–40%
[2,4]. Nevertheless, introduction of novel antifibrotic
therapies has prolonged the average life expectancy of
these patients to 9.9 years [3]. Although no cure exists
for IPF, it is possible to slow down the progression of the
disease and to reduce its exacerbations [5–9]. Currently,
only two drugs, which are nintedanib and pirfenidone, are
available on the market for the treatment of IPF.
In Turkey, two strengths (200 mg and 267 mg) of
pirfenidone are available in the market. No restrictions are
applied to the selection of the molecule or formulation by
the Turkey health authority. A physician is free to choose
the appropriate treatment based on the individual patient’s
conditions, ease-of-use, side-effect profile, and dosing

regimen. The target in the treatment is to titrate the dose
to a maximum of 2400 mg/day or 2403 mg/day.
Pirfenidone was first used in some studies conducted
in Japan, and patients with IPF were treated with 200 mg
tablets to a maximum target dose of 1800 mg/day or 2400
mg/day [10,11]. These studies have demonstrated that
the use of pirfenidone slows down the decline of forced
vital capacity (FVC) and is associated with a reduction
in exacerbations. In two major double-blind randomized
controlled trials (the ASCEND trial conducted in
Australia, Brazil, Croatia, Israel, Mexico, New Zealand,
Peru, Singapore, and the United States and the CAPACITY
trial conducted in Australia, Europe, and North America),
patients with IPF were randomly assigned to receive
either capsules containing 267 mg of pirfenidone (a total
dose of 2403 mg/day) or to placebo [12,13]. In these
trials, pirfenidone was demonstrated to reduce disease
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progression, improve progression-free survival, and
decrease mortality [12,13].
To the best of our knowledge, no data is currently
available for the use of pirfenidone with its 200 mg dose
formulation in IPF patients outside of Japan. Accordingly,
the present retrospective study aimed to investigate the
efficacy and safety of pirfenidone 200 mg tablets titrated to
the target total dose (2400 mg/day) in patients with IPF in
four university hospitals of Turkey.
2. Materials and methods
Clinical records of patients diagnosed with mild to
moderate IPF and receiving pirfenidone treatment
(pirfenidone 200 mg tablets, total daily dose of 2400 mg)
in four university hospitals (Akdeniz University, Bursa
Uludağ University, Çukurova University, and Dokuz Eylül
University) in Turkey between January 2017 and January
2019 were reviewed retrospectively and consecutively.
The present study was approved by the Clinical Research
Ethics Committee of Bursa Uludağ University Medical
Faculty (approval number: 2018-7/28, dated: 10 April
2018). The study was carried out in compliance with the
Declaration of Helsinki and in accordance with the Good
Clinical Practice (GCP) guidelines. Informed consents of
all participants were obtained.
The diagnosis of IPF was established based on the
2018 American Thoracic Society (ATS) / the European
Respiratory Society (ERS) / the Japanese Respiratory
Society (JRS) / the Latin American Thoracic Association
(ALAT) criteria [7]. Pulmonary function measurements
including percent predicted FVC (FVC%) and percentage
of diffusing capacity of the lungs for carbon monoxide
(DLCO%) were analyzed at baseline and after the patients
received pirfenidone for at least 6 months.
Disease severity was rated using the Gender-AgePhysiology (GAP) index [8]. In the GAP index, the
patients are grouped according to the variable categories
(sex, age, and physiologic variables [FVC% and DLCO%]),
and the relevant points are assigned for each group as
follows: 1) sex: females (0 point) and males (1 point), 2)
age: ≤ 60 years (0 point), 61 – 65 years (1 point), > 65
years (2 points); 3) physiologic variables: a) FVC%: ≥ 75%
(0 point), 50%–75% (1 point), and < 50% (2 points) and
b) DLCO%: > 55% (0 point), 36%–55% (1 point), and <
35% (2 points). Patients who are unable to perform the
diffusing capacity test are assigned 3 points. A total GAP
score of 0–3 indicates a mild disease, a total GAP score of
4–5 indicates intermediate disease, and a total GAP score
of 6–8 indicates a severe disease.
The patients were followed at monthly intervals for
the first 6 months and then quarterly if their condition
was stable under treatment. IPF was defined as stable
in case of no change and/or a decrease of < 10% in the

FVC%. IPF was defined as progressed in the presence of
a decrease by ≥ 10% in the FVC%. Each clinical review
included confirmation and documentation of treatment
dose, presence of any new adverse events (AEs), strategies
for the management of AEs, documentation of dose
interruptions, and hospital admissions in the preceding
months. Weight loss was defined as a reduction in body
weight by > 10% from baseline within 6 months. Cough
was defined as “worse”, “better”, or “unchanged” based on
patients’ self-report.
2.1. Statistical analysis
Statistical analyses were performed using the IBM SPSS
Statistics for Windows, Version 22.0 (IBM Corp., Armonk,
NY, USA). Descriptive statistics were expressed as mean,
standard error, or median (minimum-maximum) for
continuous variables and number (n) and percentage (%)
for categorical variables.
3. Results
The present study included 82 patients with IPF, of whom
87.8% were males with a mean age of 66 ± 1.2 years
(range, 44 - 85 years). The demographic and clinical
characteristics of the patients with IPF are summarized
in Table 1. Sixty-two (75.6%) patients had a definite usual
interstitial pneumonia (UIP) pattern on high-resolution
computed tomography (HRCT) scans, whereas 18 (22%)
patients had surgically proven UIP patterns. The mean
GAP index score in the whole study group was 3.76 ±
1.45. Accordingly, the severity of IPF among the study
population was distributed as mild to moderate.
The findings of the respiratory function tests in the
study population are summarized in Table 2. After 6
months of treatment, of 82 patients with IPF, 7 patients
discontinued the treatment due to AEs; of the remaining
75 patients, 71 (94.6%) remained stable and 4 (5.4%) had
progressive disease as evident by a decline in the FVC% by
at least 10% while on treatment (Figure), and 45 (61.3%)
had an improvement in cough.
Seven (8.5%) out of 82 IPF patients discontinued
pirfenidone due to AEs; discontinuation of treatment was
due to severe photosensitivity in 2 patients and due to
gastrointestinal complaints in 5 patients. Of the remaining
75 patients continued to treatment, 28 (37.3%) had at least
one AE associated with the treatment. The most frequently
reported AE was gastrointestinal discomfort (n = 15;
20%), followed by weight loss (n = 11; 14%), rash/itching
(n = 5; 6.7%), and photosensitivity (n = 5; 6.7%). For the
management of AEs, the patients were informed about
taking medicines with food to reduce gastrointestinal
complaints, those with weight loss were recommended
a high calorie diet at frequent intervals, and those with
rash/itching and photosensitivity were informed about
sun protection measures and recommended sunscreen
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Table 1. Demographics and clinical characteristics of the patients
with idiopathic pulmonary fibrosis at baseline.

Sex, Male / Female

Patients with IPF
n = 82
61.27 ± 8.38
44 - 85
72 / 10

BMI, kg/m2, Mean ± SE

28.3 ± 3.7

Characteristics
Age, years, Mean ± SE, Min - Max

Smoking status, n (%)

Table 2. Findings of the respiratory function tests in the study
patients.
Baseline
Mean ± SE
(n = 82)

At the end of 6th
month Mean ± SE
(n = 75)

FVC, % predicted

69.44 ± 17.04

71.42 ± 18.31

FEV1/FVC

90.56 ± 6.62

89.80 ± 6.05

DLCOadj

52.46 ± 16.74

55.43 ± 15.13

Current smokers

2 (2.4)

Quitters

58 (70.7)

SE, standard error; FVC, forced vital capacity; FEV1, forced

Never smokers

22 (26.8)

expiratory volume in 1 second; DLCOadj, adjusted diffusing
capacity of the lungs for carbon monoxide.

HRCT, n (%)
Definite UIP

62 (75.6)

Probable

11 (13.4)

Indeterminate

5 (6.1)

Alternative

4 (4.9)

Biopsy-proven UIP pattern, n (%)
Yes

18 (22.0)

No

64 (78.0)

Comorbidities as defined by the physician,
n (%)
Atherosclerotic heart disease

10 (12.2)

Hypertension

28 (34.2)

Diabetes mellitus

22 (26.8)

Arrhythmia

4 (4.9)

GAP index score, Mean ± SE

3.76 ± 1.45

IPF, idiopathic pulmonary fibrosis; Min-Max, minimummaximum; SE, standard error; BMI, body mass index; HRCT,
high-resolution computed tomography; UIP, usual interstitial
pneumonia.

creams and therapeutic local treatments for the skin.
Dose adjustment was required in 10 (12%) patients
who experienced AEs (Table 3). In these 10 patients,
pirfenidone was adjusted to a dose of 1800 mg/day.
Additionally, the average dose of pirfenidone was 2311
mg/day in the patients who completed their treatment.
The time to treatment discontinuation due to AEs varied
between 1 month and 3 months. During the treatment
period, exacerbation was observed in 2 (2.7%) patients.
4. Discussion
The present retrospective study revealed that the use of
pirfenidone 200 mg tablets for 6 months in IPF patients
was both effective and well-tolerated. Although the study
was not placebo-controlled, it was observed that the FVC%

3084

value in the study patients remained stable at 94.6% at the
end of the 6-month treatment. Weight loss was observed
in 14% of the patients.
Pirfenidone has been used in Japan for the treatment of
IPF since 2000s. Pirfenidone has been shown to be effective
in reducing the decline in FVC value and improving the
6-min walking distance [12,13]. Pirfenidone is believed
to exert its effect through transforming growth factorbeta (TGF-β) [4–6]. In their study, Azuma et al. [10]
demonstrated that as compared with placebo, pirfenidone
was associated with a reduction in FVC decline and
provided protection against exacerbations during a
9-month follow-up period. Based on its favorable efficacy
and safety profile, pirfenidone is one of the two drugs
approved for IPF treatment by the US Food and Drug
Administration (FDA) and the European Medicines
Agency (EMA). Currently, in our country, two strengths
(267 mg and 200 mg) of pirfenidone are available in the
market. Patients who were titrated to the optimal dose
with pirfenidone 200 mg tablets were included in the
present study.
In two randomized controlled trials on the efficacy
of pirfenidone in IPF patients, the FVC value was used
as a primary endpoint [12,13]. In the CAPACITY trial,
the reduction in decline in FVC at the end of 72 weeks
was reported to be significant in the patient group than
in the placebo group [12]. In the post-hoc analysis of the
placebo-controlled ASCEND (study 016; NCT01366209)
and CAPACITY (studies 004 and 006; NCT00287716 and
NCT00287729) phase III trials, Nathan et al. [14] observed
a significant difference in the declines in FVC% in favor of
the pirfenidone group. In the present study, the efficacy of
pirfenidone treatment was also evaluated based on FVC
values. Of the patients continued on pirfenidone treatment
at the end of 6 months, 94.6% had a decline in the FVC%
by <10% and were considered to have stable disease. This
finding was consistent with those in the literature. On the
other hand, in a long-term study on the outcomes of IPF
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Figure. Changes in forced vital capacity (FVC%) and diffusing capacity of the lungs for
carbon monoxide (DLCO%) after 6-month of pirfenidone treatment according to the
baseline in four patients having progressive disease.
Table 3. Adherence to pirfenidone treatment in the study patients
Actions taken

Patients with IPF
(n = 82) n (%)

No dose modification

58 (71)

Reduction in pirfenidone dose

10 (12)

Temporary discontinuation of pirfenidone 7 (8.5)
Permanent discontinuation of pirfenidone 7 (8.5)
IPF, idiopathic pulmonary fibrosis.

patients (n = 502) who received pirfenidone for 3 years,
Bando et al. [15] demonstrated that FVC was preserved
in more than 50% of their patients. Accordingly, one of
the limitations of the present study could be considered
its short evaluation period (6 months), and, thus, it should
be kept in mind that this study only provided limited
information on disease progression.
Cough is a major clinical problem among IPF patients.
The underlying mechanism is not clear and patients do
not respond to antitussive therapy [16]. In their study,
Van Manen et al. [17] reported a reduction in 24-h cough
counts by 34% after 12 weeks of pirfenidone treatment in
IPF patients. In the present study, 61.3% of the patients
had an improvement in cough after 6 months of treatment.
Although an objective scale for evaluating cough severity
was not used, which can be considered one of the limitations
of the present study, the observed improvement in cough
in 61.3% of the patients was considered important as the
present study reflects the situation in a real-life setting.
During the study period, cough was evaluated based on
patients’ self-report as “worse”, “better”, or “unchanged”.

An important finding in the present study was that a
reduction in cough frequency was demonstrated after 6
months of pirfenidone treatment in a real-life setting.
In their studies, Arai et al. [18] and Hanta et al. [19]
demonstrated a better response to pirfenidone treatment
in mild cases of IPF. Using the criteria of the Japanese
Respiratory Society, the severity of the disease is classified
based on oxygen saturation at rest and on arterial oxygen
pressure [20]. Another study conducted in Japan showed
that pirfenidone had similar effects in patients receiving a
total daily dose of 1200 mg and in those receiving a total
daily dose of 1800 mg using 200 mg tablets [11]. In their
phase III trial, Taguchi et al. [21] demonstrated a reduction
in FVC decline with pirfenidone in all grades of disease
severity and observed a better response in mild to moderate
IPF patients. Although these results have suggested that
initiation to pirfenidone at an early stage of IPF might be
associated with a better response, the study by Okuda et al.
[22] provided evidence that pirfenidone was also effective
in severe IPF patients. The above-mentioned studies
were all conducted in Japan using the 200 mg strength of
pirfenidone. In the present study, oxygen saturation was
not used as a measure of severity; however, the GAP index
was used for the assessment of disease severity [8]. Based
on their GAP scores, the present study population can be
considered to have mild to moderate disease. By the end of
the 6-month study period, a pirfenidone response similar
to the Japanese trials was demonstrated.
In many studies, the most common AE associated
with pirfenidone is gastrointestinal discomfort [12,13,23].
Nausea and vomiting and- although relatively infrequentanorexia have been reported. In the present study, at
least one AE associated with pirfenidone treatment
was observed in 28 (37.3%) patients. Gastrointestinal
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discomfort (20%), weight loss (14%), rash/itching (6.6%),
and photosensitivity (6.6%) were the most frequent AEs
in our cohort. A comprehensive safety outcome analysis
of pirfenidone conducted in a large and well-defined
IPF cohort (n = 1299), which had prospective follow-up
period of 9.9 years, pirfenidone was reported to be safe
and usually well tolerated [23]. Gastrointestinal system
and skin-related events were reported as the most common
AEs related to pirfenidone, the severity of which were
usually mild to moderate and which improved with dose
modification [23]. In that particular study, increased
aminotransferase levels, which were transient and
reversible with no clinical sequelae upon dose modification
or treatment discontinuation, were also reported mostly
in the first 6 months of treatment with pirfenidone [23].
Taking the evaluation period of the present study (6
months) into account, none of our patients had elevated
aminotransferase levels. Another AE associated with the
use of antifibrotic agents is weight loss [24]. Recent studies
have reported weight loss in patients on pirfenidone or
nintedanib. In their study investigating weight loss in IPF
patients (n = 80) using pirfenidone or nintedanib, Perelas
et al. [24] reported a 5% weight-loss in 44% of their patients
and a 10% weight loss in 19% of their patients. They also
reported a significantly more frequent weight loss in the
nintedanib group than in the pirfenidone group [24]. In
the present study, weight loss was considered an AE during
data collection and the findings were found to be consistent
with those reported in the literature. Overall, the observed
AE profile in our cohort was consistent with those reported
in the literature, and no unusual AEs were observed.
In the present study, 71% of the patients remained on
pirfenidone treatment for 6 months without a need to
modify the dose; dose adjustment was required in 10 (12%)
patients. Similarly, in a long-term study in which patients
were divided into those who used pirfenidone for less than
1 year or more than 1 year, Ogawa et al. [25] reported that
more than 65% of their patients remained on pirfenidone
therapy for 1 year or longer and that long-term use of
pirfenidone was effective and safe.
Except for photosensitivity, most AEs usually disappear
after 3 months on treatment. As was demonstrated in the
present study and reported in the literature, most AEs are
mild to moderate as they usually disappear with tapering
off or discontinuation of treatment. In phase III trials on
pirfenidone, the rate of tapering off or discontinuation
of treatment was reported as 46% and 41%, respectively
[13,14]. In the ASCEND trial, the observed AEs resulted
in discontinuation of treatment in 40 (14.4%) patients in
the pirfenidone group and in 30 (10.8%) patients in the
placebo group [13]. The most common AE that resulted
in treatment discontinuation was reported as worsening of
IPF in 3 (1.1%) patients in the pirfenidone group and in
15 (5.4%) patients in the placebo group [13]. Other AEs

3086

leading to treatment discontinuation in at least 1% of the
patients in the pirfenidone group included elevated liver
enzymes, pneumonia, rash, and weight loss, with each
occurring in 3 patients (1.1%) [13]. Following the approval
of pirfenidone in Japan in 2008, Ogura et al. [26] conducted
a post-marketing surveillance on 1371 patients. At the end
of a long follow-up over 12 months, 48.7% of the patients
were still on treatment, and the most common reason for
treatment discontinuation was AEs reported in 24.3% of
the patients. In the study on the outcomes of IPF patients
(n = 502) who received pirfenidone for 3 years by Bando
et al. [15], 37.1% of the patients discontinued treatment
in less than 1 year due to AEs and the 3-year incidence
of all AEs was reported as 32.6%. In the present study,
8.5% of the patients discontinued treatment due to AEs
at the end of the 6-month follow-up and the rate of AEs
was 37.3%. Although AEs are most frequently reported
in the first 6 months of pirfenidone treatment, treatment
discontinuation due to AEs was uncommon in the present
study. This may be partly due to the short evaluation period
(6 months) of the study. Considering the relatively short
follow-up period, the treatment discontinuation rate found
in the present study appeared to be comparable.
In addition to the limitations mentioned above,
some other limitations of the present study included its
retrospective design, small sample size, and assessment
of cough based on patients’ self-reports. Nevertheless, to
the best of our knowledge, this study was the first to report
efficacy and safety of 200 mg pirfenidone tablets titrated to
the target total dose in patients from four different regions
of Turkey; that is, outside of Japan, in a real-life setting.
In conclusion, the findings of the present study
demonstrated that FVC could be preserved for a period of
6 months in IPF patients who were titrated to the target
dose using 200 mg tablets of pirfenidone and that the
associated AEs were mild to moderate in severity and were
manageable. Treating IPF patients with 200 mg pirfenidone
tablets to the target dose could be suggested as both
efficacious and safe.
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